Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 3 studies | 41% ± 13% |
Insufficient scRNA-seq data for expression of LPA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 3755.85 | 226 / 226 | 84% | 9.29 | 340 / 406 |
| pancreas | 98% | 33.82 | 322 / 328 | 1% | 0.01 | 1 / 178 |
| prostate | 95% | 60.46 | 232 / 245 | 4% | 0.06 | 19 / 502 |
| kidney | 83% | 35.89 | 74 / 89 | 2% | 0.03 | 16 / 901 |
| ovary | 80% | 17.30 | 144 / 180 | 0% | 0.00 | 1 / 430 |
| bladder | 67% | 45.71 | 14 / 21 | 6% | 0.13 | 30 / 504 |
| adrenal gland | 62% | 13.00 | 161 / 258 | 5% | 0.14 | 12 / 230 |
| uterus | 57% | 9.84 | 97 / 170 | 6% | 0.09 | 27 / 459 |
| brain | 56% | 16.70 | 1491 / 2642 | 0% | 0.00 | 1 / 705 |
| thymus | 48% | 9.94 | 316 / 653 | 2% | 0.04 | 13 / 605 |
| lung | 37% | 5.74 | 213 / 578 | 2% | 0.03 | 21 / 1155 |
| esophagus | 31% | 5.79 | 450 / 1445 | 3% | 0.04 | 6 / 183 |
| intestine | 32% | 3.39 | 309 / 966 | 1% | 0.04 | 3 / 527 |
| skin | 11% | 1.05 | 190 / 1809 | 0% | 0 | 0 / 472 |
| adipose | 9% | 1.04 | 106 / 1204 | 0% | 0 | 0 / 0 |
| breast | 8% | 0.82 | 38 / 459 | 0% | 0.00 | 2 / 1118 |
| blood vessel | 6% | 0.45 | 75 / 1335 | 0% | 0 | 0 / 0 |
| stomach | 5% | 0.37 | 18 / 359 | 0% | 0.00 | 1 / 286 |
| muscle | 3% | 0.18 | 23 / 803 | 0% | 0 | 0 / 0 |
| heart | 3% | 0.41 | 22 / 861 | 0% | 0 | 0 / 0 |
| spleen | 2% | 5.39 | 6 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 2% | 0.16 | 16 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0008015 | Biological process | blood circulation |
| GO_0006629 | Biological process | lipid metabolic process |
| GO_0006508 | Biological process | proteolysis |
| GO_0006869 | Biological process | lipid transport |
| GO_0005615 | Cellular component | extracellular space |
| GO_0034358 | Cellular component | plasma lipoprotein particle |
| GO_0005576 | Cellular component | extracellular region |
| GO_0008201 | Molecular function | heparin binding |
| GO_0004175 | Molecular function | endopeptidase activity |
| GO_0004252 | Molecular function | serine-type endopeptidase activity |
| GO_0004866 | Molecular function | endopeptidase inhibitor activity |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0001968 | Molecular function | fibronectin binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0034185 | Molecular function | apolipoprotein binding |
| Gene name | LPA |
| Protein name | Lipoprotein, Lp(A) Apolipoprotein(a) (Apo(a)) (Lp(a)) (EC 3.4.21.-) |
| Synonyms | |
| Description | FUNCTION: Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330. . |
| Accessions | ENST00000316300.10 P08519 Q1HP67 |